Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study (ALSCELL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01639391|
Recruitment Status : Unknown
Verified December 2012 by Institut Pasteur.
Recruitment status was: Recruiting
First Posted : July 12, 2012
Last Update Posted : December 6, 2012
Patients with ALS will be included in the reference center for ALS in hospital La Pitié Salpêtrière, Paris.
The study proposes to investigate the pathophysiology of ALS by setting up a fibroblast bank for studying molecular, cellular and genetic parameters of the pathology.
iPS (induced pluripotent stem cells) and then differentiated cells will be generated.
The pathophysiology of ALS will be studied on the 3 types of cells (fibroblasts, iPS, differentiated cells).
|Condition or disease||Intervention/treatment||Phase|
|Amyotrophic Lateral Sclerosis||Procedure: skin biopsy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study|
|Study Start Date :||November 2012|
|Estimated Primary Completion Date :||August 2014|
|Estimated Study Completion Date :||August 2014|
Procedure: skin biopsy
biopsy 5mm maximum on healthy skin under local anaesthesia.
- Success of fibroblast culture, amplification, and freezing pellets [ Time Frame: 2 months ]
- Induced pluripotent Stem Cells generation success [ Time Frame: 2 years ]
- neurones, motoneurones, glial cells obtention from fibroblasts or iPS [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01639391
|Centre référent maladies rares SLA||Recruiting|
|Paris, France, 75013|
|Contact: Lucette Lacomblez, MD email@example.com|
|Contact: Vanessa Pibiri firstname.lastname@example.org|
|Principal Investigator: Lucette Lacomblez, MD|
|Principal Investigator:||Lucette Lacomblez, MD||hôpital La Pitié Salpêtrière, Paris|
|Study Chair:||Delphine Bohl, PhD||Institut Pasteur|